Main questions of β-blockers application in clinical practice: do they all the same?
Abstract
The present review shows the modern view on β-blockers in different clinical situations. Class β-blockers is a heterogeneous group in terms of clinical use. Several variants of β-blockers, especially non-selective, have negative effects and cannot be used in several clinical situations (metabolic disorders, chronic obstructive pulmonary disease, peripheral arteriosclerosis). Modern superselective β-blockers, including Betaloc ZOK, does not possess the mentioned adverse effects and can be widely used in clinical practice, even in case of metabolic syndrome, type 2 diabetes and chronic obstructive pulmonary disease. Another problem associated with β-blockers is the rare application of the drug and the underdosing of the drug. In this regard, it is very necessary for the practitioner not to be afraid and to start prescribing them in the recommended therapeutic doses according to the instructions for the medical applications for drugs in different clinical situations.
About the Author
D. V. Nebieridze
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Диагностика и лечение артериальной гипертензии. Российские рекомендации V пересмотра. Кардиологич. вестн. 2015; 10 (1): 3-30.
2. Диагностика и лечение хронической ишемической болезни сердца. Клинические рекомендации Минздрава России, 2013 г. РКНПК [Электронный ресурс], 10.12.2014. URL: http://www.cardioweb.ru/klinicheskie-rekomendatsii
3. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН. Сердечная недостаточность. 2013; 14 (7): 379-472.
4. Collins R, Peto R, Mac Mahon S et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term - reductions of blood pressure - an overview of the unconfined randomized drug trials in an epidemiological context. Lancet 1990; 335: 827-38.
5. Kaplan M. Metabolic Aspects of Hypertension. London: Science press, 1994.
6. Viskin S, Kitzis I, Lev E et al. Treatment with beta - adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. JACC 1995; 25: 1327-32.
7. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991, 14 (Suppl. 4): 39-47.
8. Lithell H. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-9.
9. Reneland R, Alvares E, Andersson P.L et al. Induction of insulin resistance by beta - blockade but not by ACE-inhibition: long - term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14: 175-80.
10. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol or HCTZ alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension 1985; 7: 1008-16.
11. The Working Group on Hypertension in diabetes: Statement on hypertension in diabetes mellitus. Final report. Arch Int Med 1987; 147: 830-42.
12. Pool P.E, Seagren S.C, Salel A.F: Metabolic consequences of treating hypertension. Am J Hypertens 1991; 4: 494-502.
13. Weidmann P, Feffier C, Saxenhofer H et al. Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988; 35 (Suppl. 6): 118-34.
14. Pepine C.J, Handberg E.M, Cooper-De Hoff R.M et al. A Calcium Antagonist vs a Non - Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290 (21): 2805-16.
15. The ALLHAT Officers and Coordinators Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.
16. Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
17. Beevers D.G. The end of beta - bockers for uncomplicated hypertension? Lancet 2005; 366: 1510-2.
18. Kronig B. Hertz Kreislauf. J Clin Pharmacol 1990; 30: S28-S32. 28. 1990; 22: 224-9.
19. Falkner B, Kushner H. Treatment With Metoprolol Succinate, a Selective Beta Adrenergic Blocker, Lowers Blood Pressure Without Altering Insulin Sensitivity in Diabetic Patients. J Clin Hypertens 2008; 10: 51-7.
20. Gibbons R.J, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guidelines for themanagement of patientswith chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33 (7): 2092-197.
21. Kolloch R, Legler U.F, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-34.
22. Кобалава Ж.Д., Киякбаев Г.К., Хомицкая Ю.В., Шаваров А.А. Достижение целевого уровня частоты сердечных сокращений покоя у пациентов со стабильной стенокардией и артериальной гипертонией на фоне терапии β-адреноблокаторами в реальной клинической практике. Кардиология. 2013; 7: 1-11.
23. Толпыгина С.Н., Марцевич С.Ю. Эффективность и безопасность высоких доз метопролола пролонгированного действия при лечении пациентов со стабильным течением ишемической болезни сердца. Рациональная фармакотерапия в кардиологии. 2008; 5: 46-52.
24. The MERIT-HF investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Interven tion Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
Review
For citations:
Nebieridze D.V. Main questions of β-blockers application in clinical practice: do they all the same? Systemic Hypertension. 2016;13(3):21-24. (In Russ.)
Views:
173
Email this article 